DDInter1678 DDInter1676
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Sirolimus {u} (Compound) binds {v} (Gene) ABCB1
Sirolimus {u} (Compound) upregulates {v} (Gene) WDR13
Sirolimus {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Immunologic Activity
Sirolimus {u} (Compound) downregulates {v} (Gene) IMP3
Sirolimus {u} (Compound) causes {v} (Side Effect) Aspartate aminotransferase increased
Sirolimus {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Sirolimus {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lansoprazole
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Sirolimus (Compound) resembles Pimecrolimus (Compound)
Sirolimus (Compound) binds ABCB1 (Gene)
Sirolimus (Compound) upregulates WDR13 (Gene)
Sirolimus (Compound) is included by Decreased Immunologic Activity (Pharmacologic Class)
Sirolimus (Compound) downregulates IMP3 (Gene)
Sirolimus (Compound) causes Aspartate aminotransferase increased (Side Effect)
Sirolimus may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Sirolimus may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib